Business Context and Reporting Period
Company: EyePoint, Inc. (EYPT)
Filing Type: Form 8-K (Current Report)
Date of Report: July 13, 2026
Event Date: July 17, 2026 (Effective Date of Settlement)
Context: The Company entered into a Settlement Agreement with the U.S. Department of Justice (DOJ), the Office of Inspector General of the Department of Health and Human Services (OIG-HHS), and the Defense Health Agency (DHA) to resolve potential claims regarding alleged civil violations related to sales, marketing, and promotional practices for the product DEXYCU® (commercialized 2019–2023).
Key Financial Metrics and Obligations
This filing details specific settlement obligations rather than standard operating financial metrics (revenue, profit, cash flow). The filing does not provide current revenue, profit, or liquidity figures.
- Total Settlement Payment: $4,678,981.86 plus interest at 4.25% per annum from January 28, 2026.
- Payment Allocation:
- $4,657,463.18 (plus interest) to the United States.
- $21,518.68 (plus interest) to participating states.
- Attorneys' Fees: $166,500 payable to relator's counsel.
- Payment Timeline: Settlement payment due within 14 days of the Effective Date; attorneys' fees due within 60 days.
- Funding Source: The Company intends to use cash on hand.
Material Changes and Agreements
Settlement Agreement:
- Resolves claims under the False Claims Act, Civil Monetary Penalties Law, and Administrative False Claims Act.
- Does not constitute an admission of liability by the Company.
- Results in the dismissal of the civil action filed by the relator and releases the Company from civil or administrative monetary liability regarding the "Covered Conduct."
Corporate Integrity Agreement (CIA):
- Entered into on July 13, 2026, with OIG-HHS.
- Term: Five years.
- Requirements: Maintain a Compliance Officer and Committee, board oversight, retain a compliance expert, provide training, establish written policies, engage an independent review organization, screen employees, and implement risk assessments.
- Consequence of Non-Compliance: Potential monetary penalties or exclusion from Medicare, Medicaid, and other federal health care programs.
Outlook, Risks, and Management Commentary
Management Commentary: The Company states the settlement avoids the uncertainty and expense of protracted litigation.
Risks and Contingencies:
- Compliance Risk: Failure to comply with the five-year Corporate Integrity Agreement could result in exclusion from federal health care programs, which would materially impact the Company's ability to sell products.
- Financial Impact: Immediate cash outflow for the settlement amount and ongoing costs associated with compliance requirements (e.g., independent review organization, compliance staff).
Key Facts for Investor Verification
- Verify the Company's current cash on hand to ensure it can cover the approximately $4.85 million total immediate liability (settlement plus fees) without operational disruption.
- Review the full text of the Corporate Integrity Agreement (Exhibit 10.2) to assess the specific operational burdens and costs of the five-year compliance term.
- Confirm the status of DEXYCU® commercialization, as the settlement relates to practices from 2019 to 2023, to determine if any residual reputational or regulatory risks remain for current or future products.
- Monitor future filings for any additional penalties or findings related to the "Covered Conduct" that may arise if the Company fails to meet CIA obligations.